<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01246895</url>
  </required_header>
  <id_info>
    <org_study_id>CG-CIP04-P</org_study_id>
    <nct_id>NCT01246895</nct_id>
  </id_info>
  <brief_title>Follow-Up Study Evaluating The Long Term Safety and Efficacy of BST-CarGel and Microfracture Repair of the Knee</brief_title>
  <official_title>Follow-up Study Evaluating The Long-Term Safety and Efficacy of BST-CarGel® and Microfracture In Repair of Focal Articular Cartilage Lesions on The Femoral Condyle (Extension Study of Protocols CG-CIP01-P &amp; CG-CIP02-P)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Piramal Healthcare Canada Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Piramal Healthcare Canada Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This follow-up study will evaluate the effects of BST-CarGel® application to a microfractured
      lesion (investigational) and microfracture alone (control) for up to 5 years from treatment
      in subjects, treated under Protocols CG-CIP01-P and CG-CIP02-P, and will serve as a post
      approval study for these Protocols, in support of a commercial application. The lesions
      treated under Protocols CG-CIP01-P and CG-CIP02-P were focal lesions of articular cartilage,
      grade 3 or 4 (either ICRS or Outerbridge classification) on the medial and lateral femoral
      condyles of the knee, and were classified as either acute or chronic.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cartilage repair currently remains a problematic orthopedic concern with no effective
      solution. The development of new surgical techniques or therapies is critical in meeting this
      medical need.

      Clinical data regarding the long-term durability of repair tissue resulting from cartilage
      repair techniques such as microfracture, autologous chondrocyte implantation or mosaicplasty
      is lacking. Only two studies, one comparative and one uncontrolled, have examined long-term
      repair outcomes (over 4 years). These studies reinforced the concept that further studies are
      needed to identify a technique or product that will lead to long-term clinical benefit
      through improved cartilage repair efficacy.

      BST-CarGel® is a medical device derived from chitosan applied to a microfractured lesion and
      has been shown to promote the quantity and quality of cartilage repair tissue in animals. The
      efficacy and safety of BST-CarGel® is currently being evaluated in humans as compared to the
      standard of care treatment, microfracture, in a 12 month international study in Canada,
      Europe and Korea under Protocols CG-CIP01-P and CG-CIP02-P. When these protocols were
      designed and carried out, the BST-CarGel® technology belonged to BioSyntech Canada Inc.
      Afterwards, the technology was acquired by Piramal Healthcare (Canada) Ltd. which is now the
      owner of the technology and the sponsor for this Extension Study CG-C1P04.

      This follow-up study will evaluate the long-term effects (5 yrs) of BST-CarGel® +
      microfracture and microfracture alone in subjects treated in the pivotal and sub-studies.

      All eligible subjects (maximum 80) who were treated under Protocols CG-CIP01-P and CG-CIP02-P
      and completed the required 12 month follow-up period will be asked to participate in this
      follow-up study.

      The stratification from Protocols CG-CIP01-P and CG-CIP02-P (investigational site and lesion
      type) will be retained for the purposes of the follow-up study, and all third parties such as
      the MRI central reading facility will remain blinded to the treatment received under
      Protocols CG-CIP01-P and CG-CIP02-P.

      Comparisons between the two treatment groups will be performed.

      The following assessments will be done annually at years 3 and/or 4 and 5 post -treatment
      under Protocols CG-CIP01-P and CG-CIP02-P in subjects treated with BST-CarGel + microfracture
      or microfracture alone:

        1. Analyses of tissue repair will be carried out based on the degree of lesion filling and
           quality of repair tissue using MRI

        2. The general health status of subjects will be captured in the case report form (CRF) and
           will include the subject's overall health status, treated knee status, adverse events
           (AEs) and concomitant medications.

        3. The assessment of the subject's knee pain, stiffness, functional ability and quality of
           life through self-assessment questionnaires (Western Ontario and McMaster Universities
           osteoarthritis index (WOMAC) and short-form-36 (SF-36v2)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of Lesion Filling (%Fill) by Repair Tissue at Degree of Lesion Filling (%Fill) by Repair Tissue at 5 Years Through MRI.</measure>
    <time_frame>5 years</time_frame>
    <description>Degree of lesion filling (repair tissue volume) as measured by quantitative MRI at 5 Years post-treatment compared to the debrided lesion 1-month post-treatment (baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Repair Tissue Quality (T2 MRI)</measure>
    <time_frame>5 years</time_frame>
    <description>Tissue quality of the repair tissue as measured by T2 MRI as an index for collagen-based structure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline for Knee-related Pain, Stiffness and Function at 5 Years (WOMAC Parts A, B, C)</measure>
    <time_frame>5 years</time_frame>
    <description>The three sub-scales: 1) Pain, 2.) stiffness and 3.) function scores ranged from 0-10. Pain had 5 items and stiffness had 2 items, and function had 17 items. The total score for pain ranged from 0 no pain to 50 worst pain. The total score for stiffness ranged from 0 no stiffness to 20 worst stiffness. The total score for function raged from 0 no function to 170 worst function. A higher score indicates a better health state improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Adverse Events Until 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>Safety was assessed by recording the number of participants with Adverse Events (AEs) and their severity from the time of ICF signing up to 5 years post-treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage Change in Quality of Life Assessed Using the SF-36 Questionnaire.</measure>
    <time_frame>1 and 5 years</time_frame>
    <description>SF-36 v2 includes 2 aggregate measures—Physical and Mental components—derived from 8 subscales. Least squares means are adjusted for baseline. Higher positive scores indicate better results. Scoring ranges from 0 to 100%.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">67</enrollment>
  <condition>Knee Injuries</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <description>Microfracture with BST-CarGel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Microfracture without BST-CarGel</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microfracture with BST-CarGel</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microfracture without BST-CarGel</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that have been treated under either protocol CG-CIP01 or CG-CIP02
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject was treated under Protocol CG-CIP01 or CG-CIP02 and completed 12 month
             follow-up period

          -  The subject has understood and signed a Research Ethics Board(REB) approved Informed
             Consent Form (ICF)

        Exclusion Criteria:

          -  The subject was not treated under Protocol CG-CIP01-P or CG-CIP02-P

          -  The subject did not complete 12 month follow-up period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Stanish, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orthopaedic and Sport Medicine - Dalhousie University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary Sports Medicine Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simon Fraser Orthopaedic Fund, Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Preservation Centre of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pan Am Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic and Sport Medicine Clinic of Nova Scotia</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 4M2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakville Trafalgar Memorial Hospital</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 3L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sports Medicine Center, Carleton University</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1S 5B6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre, Orthopaedics Research Office</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sacré-Coeur de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA-Pavillon Enfant-Jésus</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles LeMoyne, Unité d'investigation non invasive</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FREMAP Centro de Prevención y Rehabilitatión</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cirugia Ortopedica y Traumatologia, Medicina del Deporte</name>
      <address>
        <city>Gijon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://bst-cargel.piramal.com/</url>
    <description>Healthcare professionals please follow here - http://bst-cargel.piramal.com/content/medical-professional</description>
  </link>
  <results_reference>
    <citation>Shive MS, Stanish WD, McCormack R, Forriol F, Mohtadi N, Pelet S, Desnoyers J, Méthot S, Vehik K, Restrepo A. BST-CarGel® Treatment Maintains Cartilage Repair Superiority over Microfracture at 5 Years in a Multicenter Randomized Controlled Trial. Cartilage. 2015 Apr;6(2):62-72. doi: 10.1177/1947603514562064.</citation>
    <PMID>26069709</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <results_first_submitted>January 7, 2016</results_first_submitted>
  <results_first_submitted_qc>June 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 24, 2018</results_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cartilage repair</keyword>
  <keyword>Cartilage</keyword>
  <keyword>Knee</keyword>
  <keyword>Knee Pain</keyword>
  <keyword>Microfracture</keyword>
  <keyword>Arthroscopy</keyword>
  <keyword>Bone Marrow Stimulation</keyword>
  <keyword>Chondrogenesis</keyword>
  <keyword>Scaffold</keyword>
  <keyword>Chitosan</keyword>
  <keyword>Articular Cartilage Repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Knee Injuries</mesh_term>
    <mesh_term>Fractures, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not planned</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All eligible subjects who were treated under Protocol CG-CIP01-P and completed the required 12-month follow-up period were asked to participate in this follow-up study. Ultimately, 67 subjects signed an ICF to enter the study and the screening process.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Microfracture + BST-CarGel</title>
          <description>Microfracture with BST-CarGel</description>
        </group>
        <group group_id="P2">
          <title>Microfracture Alone</title>
          <description>Microfracture without BST-CarGel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Sample size determination for the 1-year trial was previously reported. All treated participants who enrolled in the extension study were included in the efficacy analyses, which were performed according to a preapproved statistical analysis plan.</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>Microfracture with BST-CarGel</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Microfracture without BST-CarGel</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.3" spread="9.7"/>
                    <measurement group_id="B2" value="40.1" spread="10.1"/>
                    <measurement group_id="B3" value="36.8" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrew/Withdrawn</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Degree of Lesion Filling (%Fill) by Repair Tissue at Degree of Lesion Filling (%Fill) by Repair Tissue at 5 Years Through MRI.</title>
        <description>Degree of lesion filling (repair tissue volume) as measured by quantitative MRI at 5 Years post-treatment compared to the debrided lesion 1-month post-treatment (baseline).</description>
        <time_frame>5 years</time_frame>
        <population>33 out of 34 BST-CarGel with percentage lesion filled measurement. 1 aberrant imaging datapoint from 1 patient out of 34 patients was removed from the Experimental group</population>
        <group_list>
          <group group_id="O1">
            <title>Microfracture + BST-CarGel</title>
            <description>Microfracture with BST-CarGel</description>
          </group>
          <group group_id="O2">
            <title>Microfracture Alone</title>
            <description>Microfracture without BST-CarGel</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Lesion Filling (%Fill) by Repair Tissue at Degree of Lesion Filling (%Fill) by Repair Tissue at 5 Years Through MRI.</title>
          <description>Degree of lesion filling (repair tissue volume) as measured by quantitative MRI at 5 Years post-treatment compared to the debrided lesion 1-month post-treatment (baseline).</description>
          <population>33 out of 34 BST-CarGel with percentage lesion filled measurement. 1 aberrant imaging datapoint from 1 patient out of 34 patients was removed from the Experimental group</population>
          <units>Percentage of lesion filled (%)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.79" spread="1.16"/>
                    <measurement group_id="O2" value="86.96" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</p_value_desc>
            <method>general estimating equations (GEE)</method>
            <method_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Repair Tissue Quality (T2 MRI)</title>
        <description>Tissue quality of the repair tissue as measured by T2 MRI as an index for collagen-based structure.</description>
        <time_frame>5 years</time_frame>
        <population>5 aberrant imaging datapoint from 5 patients out of 34 patients were removed from the Experimental group and 4 aberrant imaging datapoint from 4 patients out of 34 patients were removed from the Control group</population>
        <group_list>
          <group group_id="O1">
            <title>Microfracture + BST-CarGel</title>
            <description>Microfracture with BST-CarGel</description>
          </group>
          <group group_id="O2">
            <title>Microfracture Alone</title>
            <description>Microfracture without BST-CarGel</description>
          </group>
        </group_list>
        <measure>
          <title>Repair Tissue Quality (T2 MRI)</title>
          <description>Tissue quality of the repair tissue as measured by T2 MRI as an index for collagen-based structure.</description>
          <population>5 aberrant imaging datapoint from 5 patients out of 34 patients were removed from the Experimental group and 4 aberrant imaging datapoint from 4 patients out of 34 patients were removed from the Control group</population>
          <units>T2 relaxation time (ms)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.68" spread="5.25"/>
                    <measurement group_id="O2" value="90.41" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <p_value_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</p_value_desc>
            <method>general estimating equations (GEE)</method>
            <method_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline for Knee-related Pain, Stiffness and Function at 5 Years (WOMAC Parts A, B, C)</title>
        <description>The three sub-scales: 1) Pain, 2.) stiffness and 3.) function scores ranged from 0-10. Pain had 5 items and stiffness had 2 items, and function had 17 items. The total score for pain ranged from 0 no pain to 50 worst pain. The total score for stiffness ranged from 0 no stiffness to 20 worst stiffness. The total score for function raged from 0 no function to 170 worst function. A higher score indicates a better health state improvement.</description>
        <time_frame>5 years</time_frame>
        <population>1 datapoint not made available from 1 patient out of 34 patients in the Experimental group</population>
        <group_list>
          <group group_id="O1">
            <title>Microfracture + BST-CarGel</title>
            <description>Microfracture with BST-CarGel</description>
          </group>
          <group group_id="O2">
            <title>Microfracture Alone</title>
            <description>Microfracture without BST-CarGel</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline for Knee-related Pain, Stiffness and Function at 5 Years (WOMAC Parts A, B, C)</title>
          <description>The three sub-scales: 1) Pain, 2.) stiffness and 3.) function scores ranged from 0-10. Pain had 5 items and stiffness had 2 items, and function had 17 items. The total score for pain ranged from 0 no pain to 50 worst pain. The total score for stiffness ranged from 0 no stiffness to 20 worst stiffness. The total score for function raged from 0 no function to 170 worst function. A higher score indicates a better health state improvement.</description>
          <population>1 datapoint not made available from 1 patient out of 34 patients in the Experimental group</population>
          <units>Percentage change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain at 5 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.37" spread="1.47"/>
                    <measurement group_id="O2" value="-16.56" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stiffness at 5 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.63" spread="0.72"/>
                    <measurement group_id="O2" value="-6.68" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Function at 5 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.52" spread="4.57"/>
                    <measurement group_id="O2" value="-62.10" spread="3.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WOMAC subscale - Pain</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.474</p_value>
            <p_value_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</p_value_desc>
            <method>general estimating equations (GEE)</method>
            <method_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WOMAC subscale - Stiffness</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.236</p_value>
            <p_value_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</p_value_desc>
            <method>general estimating equations (GEE)</method>
            <method_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>WOMAC subscale - Physical function</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.326</p_value>
            <p_value_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</p_value_desc>
            <method>general estimating equations (GEE)</method>
            <method_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Adverse Events Until 5 Years</title>
        <description>Safety was assessed by recording the number of participants with Adverse Events (AEs) and their severity from the time of ICF signing up to 5 years post-treatment.</description>
        <time_frame>5 years</time_frame>
        <population>Participants who experienced adverse events</population>
        <group_list>
          <group group_id="O1">
            <title>Microfracture + BST-CarGel</title>
            <description>Microfracture with BST-CarGel</description>
          </group>
          <group group_id="O2">
            <title>Microfracture Alone</title>
            <description>Microfracture without BST-CarGel</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Adverse Events Until 5 Years</title>
          <description>Safety was assessed by recording the number of participants with Adverse Events (AEs) and their severity from the time of ICF signing up to 5 years post-treatment.</description>
          <population>Participants who experienced adverse events</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AE's</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with unanticipated procedure-related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with anticipated procedure-related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with unanticipated device-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with anticipated device-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with serious adverse events SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants discontinued from study because of an</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant death over the 5-year follow up period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Physical count</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage Change in Quality of Life Assessed Using the SF-36 Questionnaire.</title>
        <description>SF-36 v2 includes 2 aggregate measures—Physical and Mental components—derived from 8 subscales. Least squares means are adjusted for baseline. Higher positive scores indicate better results. Scoring ranges from 0 to 100%.</description>
        <time_frame>1 and 5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Expiremental</title>
            <description>Microfracture with BST-CarGel</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Microfracture without BST-CarGel</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Quality of Life Assessed Using the SF-36 Questionnaire.</title>
          <description>SF-36 v2 includes 2 aggregate measures—Physical and Mental components—derived from 8 subscales. Least squares means are adjusted for baseline. Higher positive scores indicate better results. Scoring ranges from 0 to 100%.</description>
          <units>Percent change from baseline</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical component - Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.01" spread="1.43"/>
                    <measurement group_id="O2" value="14.37" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component - Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.12" spread="1.63"/>
                    <measurement group_id="O2" value="14.48" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component - Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" spread="1.42"/>
                    <measurement group_id="O2" value="0.49" spread="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component - Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="1.30"/>
                    <measurement group_id="O2" value="-0.17" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SF-36 v2 Physical component</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.478</p_value>
            <p_value_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</p_value_desc>
            <method>general estimating equations (GEE)</method>
            <method_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>SF-36 v2 Mental component</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.125</p_value>
            <p_value_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</p_value_desc>
            <method>general estimating equations (GEE)</method>
            <method_desc>P-values were obtained using general estimating equations (GEE) for longitudinal analysis of repeated correlated measures.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected from signature of ICF (follow-up study) to 5 year follow-up.</time_frame>
      <desc>The incidence of AEs, SAEs, and incidents have been summarized by SOC and preferred terms according to MedDRA preferred terminology for each treatment group, frequency, maximum severity, and relationship to procedure or device.</desc>
      <group_list>
        <group group_id="E1">
          <title>Microfracture + BST-CarGel</title>
          <description>Microfracture with BST-CarGel</description>
        </group>
        <group group_id="E2">
          <title>Microfracture Alone</title>
          <description>Microfracture without BST-CarGel</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>LEFT KNEE THROBBING PAIN</sub_title>
                <description>Unanticipated procedure/device-related. Preferred Term: Arthralgia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>LEFT KNEE MEDIAL CLICKING THAT INITIATES THROBBING</sub_title>
                <description>Unanticipated procedure/device-related. Preferred Term: Arthralgia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>PAIN LEFT KNEE/ ABOVE KNEE CAP</sub_title>
                <description>Anticipated procedure-related. Preferred Term: Arthralgia.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>FEELING OF RIGHT KNEE GIVING OUT</sub_title>
                <description>Anticipated procedure-related. Preferred Term: Arthralgia.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>RIGHT KNEE PAIN AFTER EXERCISE</sub_title>
                <description>Anticipated procedure-related. Preferred Term: Arthralgia</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>MIGRAINES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Since the sample size was not predetermined, the statistical methods were used in a conditional fashion such that those that were determined to be invalid or inappropriate upon data review were discarded or replaced by more appropriate analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David Castelo, Clinical Research Manager</name_or_title>
      <organization>Piramal Healthcare (Canada) Limited - Bio-Orthopaedics Division</organization>
      <phone>450-686-2437 ext 313</phone>
      <email>david.castelo@piramal.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

